udd-Chiari syndrome (BCS) is a vascular disorder characterized by obstruction of hepatic venous outflow from the hepatic venules to the entrance of the inferior vena cava (IVC) into the right atrium.
scholars reported a high frequency (>70%) of reocclusion in patients who underwent balloon dilation alone, and primary stent placement was suggested in both MOVC and SOVC patients. [14] [15] [16] In this study, we compared long-term outcomes of endovascular management, including balloon dilation alone and adjunctive stent placement, in primary BCS patients with MOVC and SOVC. We also determined the risk factors for postoperative reocclusion and explored the optimal endovascular strategy for these conditions (Table I in 
Methods

Patients
This retrospective cohort study was approved by the ethics committee at the Affiliated Hospital of Xuzhou Medical College. All patients in our department received detailed information about the endovascular procedures. Patients provided written informed consent before treatment. Inclusion criteria were as follows: (1) patients aged between 18 and 80 years, (2) primary BCS with MOVC or SOVC, (3) occlusion of an IVC segment above the ostium of the renal veins, (4) at least 1 patent hepatic vein or accessory hepatic vein, and (5) no acute thrombosis in the IVC or hepatic veins. Exclusion criteria were as follows: (1) patients with secondary BCS, (2) IVC patency or stenosis, (3) IVC occlusion involving the ostium of the renal veins, (4) obstruction of all 3 main hepatic veins and the accessory hepatic vein, (5) primary BCS complicated by hepatocellular carcinoma, (6) contraindications for anticoagulation, and (7) severe hepatic, renal, or heart failure.
From January 2009 to December 2014, 507 consecutive patients with primary BCS underwent endovascular management in our department. Among them, IVC obstruction was identified in 357 patients. On the basis of the inclusion and exclusion criteria, 92 patients were excluded and 265 patients (mean age, 49.1±10.3 years; range, 18-79 years) were included in this study. Patient diagnoses were established on the results of abdominal ultrasonography (265/265), magnetic resonance angiography (230/265), or computed tomographic angiography (35/265) before treatment. Finally, IVC angiography was performed in all patients to identify the site, degree, and extent of IVC obstruction. According to the length of the IVC occlusion, patients were classified into the MOVC group (n=136) or the SOVC group (n=129). The endovascular treatment strategy was recorded, and the treatment steps are shown in Figure 1 . Baseline clinical characteristics of all 265 patients are summarized in Table 1 . Underlying pathogenic factors for BCS were identified in 31 patients. Twenty patients had positive anticardiolipin IgG antibodies. Six patients had antithrombin deficiency. Hyperhomocysteinemia was present in 5 patients. JAK2 V617F mutation and protein C and protein S were not examined.
Endovascular Procedures
Under local anesthesia, a 6F catheter sheath was placed in the right femoral vein, and a 5F pigtail catheter (Cook Medical, Bloomington, IN) was advanced into the IVC below the distal part of the obstruction via the sheath. Angiography was performed, and the pigtail catheter was retained at the distal end of the IVC occlusion as a localizer. We punctured the right jugular vein and inserted a 6F catheter sheath. A 5F angiographic catheter (Cordis Corp, Miami, FL) was advanced to the proximal end of the IVC and angiography was performed. Combination of the 2 venographic results delineated the extent of IVC occlusion and collateral circulation.
A steel needle with a curved head 17, 18 was advanced through the 5F angiographic catheter via the right jugular approach to penetrate the IVC occlusion from the proximal end under fluoroscopic guidance. The weakest point of the IVC obstruction was carefully probed, rather than using brute force to penetrate it. Once the steel needle went through the IVC occlusion, the 5F angiographic catheter was advanced along the steel needle track. The needle was withdrawn, and an ultrasmooth exchange guidewire (Cook Medical; 260-cm long, 0.035 inch in diameter) was advanced through the 5F angiographic catheter to the distal end of the IVC. Then a balloon catheter (Optimed, Ettlimgen, Germany; 40-mm long, 20, 24, 26, or 28 mm in diameter) was placed across the occlusion via the exchange guidewire. The diameter of the balloon used was 20% more than the diameter of the IVC below the occlusion. The balloon was manually
WHAT IS KNOWN
• Endovascular intervention comprising balloon dilation and stent placement has become the treatment of choice for primary Budd-Chiari syndrome (BCS) with membranous and segmental inferior vena cava (IVC) occlusion because of its minimal invasiveness and satisfactory efficacy.
• To date, however, few studies have compared the long-term outcomes of endovascular management between membranous and segmental IVC occlusion in patients with primary BCS.
WHAT THE STUDY ADDS
• The long-term outcome of endovascular treatment was better for primary BCS patients with membranous IVC occlusion than for those with segmental IVC occlusion.
• For BCS patients with membranous IVC occlusion, balloon dilation alone resulted in favorable outcomes, suggesting stenting can be reserved for technical angioplasty failure. For BCS patients with segmental IVC occlusion, the efficacy of balloon dilation alone was poor and routine stenting should be considered.
• Increased serum alkaline phosphatase and segmental IVC occlusion were independent risk factors for reocclusion in patients with BCS. The purpose of the dilation was disappearance of the waist at the obstruction site, which was confirmed by fluoroscopy. After dilation, the balloon catheter was removed. Subsequently, IVC angiography was performed through the right femoral vein to evaluate the extent of IVC patency. The pressure gradient between the IVC and the right atrium was recorded before and after treatment. Then, a 5F angiographic catheter was inserted through the right femoral vein into the hepatic vein or the accessory hepatic vein to perform angiography. If the IVC occlusion could not be penetrated through the right jugular vein, penetration of the occluded IVC segment from the distal end was performed through the right femoral vein.
If IVC recoil (>50%) was present or the IVC-right atrium pressure gradient was higher than 15 cmH 2 O (1 cmH 2 O=0.098 kPa) after balloon dilation alone, a self-expandable stainless steel Z-type IVC stent (Shenyang Yongtong Technology Co, Ltd, Shenyang, China; 70-, 80-, or 90-mm long, 28 or 30 mm in diameter) was deployed to the site of the IVC obstruction as a bail-out, using a 12F delivery sheath (Check-Flo Performer, Cook Incorporated, Bloomington, IN) through the right femoral vein. If the IVC diameter below the occlusion was <26 mm, a 28-mm diameter stent was used. Otherwise, a 30-mm diameter stent was chosen. The length of the used stent was required to cover the entire IVC obstruction without covering the opening of the renal veins.
Post-Treatment Observations and Follow-Up
After endovascular treatment, all patients were prescribed subcutaneous low-molecular-weight heparin (Nadroparin Calcium, 5000 U/12 hours) for 3 to 4 days, followed by warfarin sodium for at least 1 year. The international normalized ratio was maintained at 2 to 3. Follow-up was performed at 1, 3, 6, and 12 months after treatment and then annually or whenever symptoms recurred. Follow-up included clinical signs, imaging workups (abdominal color Doppler ultrasound, magnetic resonance angiography, or computer tomographic angiography), and laboratory test results (coagulation function, liver and kidney function). Patients were followed up until death or the end of the study period.
Statistical Analysis
Quantitative data are expressed as mean±SD, and they were compared with independent sample t test. The changes in the IVC-right atrium pressure gradient before and after treatment were assessed with a paired-samples t test. Categorical data are expressed as a ratio (or percentage), and the χ 2 test or Fisher exact test was used for comparisons. The follow-up time was calculated as the time from the date of primary endovascular treatment to the date of patients' death or December 31, 2014. Patients who died during follow-up and patients lost to follow-up were censored at the time of last known contact. Missing outcome data because of technical failure or loss to follow-up were not included in the analyses of long-term outcomes. Cumulative patency rates were calculated with Kaplan-Meier curves and compared using the log-rank test. A Cox proportional hazards regression model was used to analyze risk factors for reocclusion. The proportional hazard assumption in the Cox model was assessed with the Schoenfeld residuals method, 19 and all proportionality assumptions were appropriate. Baseline variables were first investigated by univariate Cox proportional hazards regression analysis. Candidate variables with a P value of <0.10 in the univariate analyses were considered in the multivariate adjusted model. A difference with P<0.05 was considered statistically significant. All statistical analyses were performed using SPSS, version 16.0 (SPSS Inc, Chicago, IL).
Results
Immediate Outcomes
Technical success was defined as eliminated IVC obstruction along with a decrease in the IVC-right atrium pressure gradient. The overall technical success rate of endovascular (Table 2) .
Technical failure occurred in 2 patients with SOVC. The occluded IVC segment was rigid in both the patients. After IVC penetration, the balloons used for dilation ruptured in both the patients (20-mm balloon in 1 patient and 24-mm balloon in the other patient). No further endovascular treatment was performed in these patients.
Three patients (1.1%) had serious intraoperative complications. Two patients with MOVC developed pericardial tamponade after the puncture needle was inserted into the pericardium by mistake. The 2 patients were treated successfully using a 4F pigtail catheter for pericardial drainage. One patient with SOVC sustained IVC rupture and hemorrhage caused by dilation of a 24-mm balloon catheter. A 26-mm balloon was used for temporary plugging, followed by a covered stent (70-mm long and 28 mm in diameter; Shanghai MicroPort Co, Ltd, Shanghai, China) placed at the ruptured portion through the right jugular vein. Successful IVC repair was achieved in this patient. There were no procedure-related deaths. No stents were dislocated into the right atrium.
Long-Term Outcomes
Patients in this study were followed up for 3 to 72 (mean, 43.2±20.0) months after treatment. Eighteen patients were lost to follow-up. Of the remaining 245 patients, 36 experienced reocclusion during follow-up (Table 3) . Twenty-four patients with reocclusion underwent another balloon dilation or stent placement, and IVC patency was again achieved. The other 12 patients refused further intervention. Of the 52 stented cases, 46 cases of mild intimal hyperplasia were found by ultrasound examination. There were other 6 cases of reocclusion at the end of the study follow-up. No significant difference in the occlusion length of IVC was detected between patients with 
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The cumulative 1-, 3-, and 5-year primary IVC patency rates of the 245 cases were 93.5%, 85.2%, and 76.1%, respectively. The cumulative 1-, 3-, and 5-year secondary IVC patency rates were 98.7%, 94.9%, and 89.9%, respectively. The overall cumulative 1-, 3-, and 5-year primary IVC patency rates were 98.3%, 90.7%, and 83.8% in the MOVC group and 88.3%, 79.1%, and 67.9% in the SOVC group, respectively (P=0.007). For patients who underwent balloon dilation alone, the cumulative 1-, 3-, and 5-year primary IVC patency rates were 98.2%, 91.0%, and 83.2% in the MOVC group and 83.7%, 76.9%, and 62.9% in the SOVC group, respectively (P=0.001). For patients who underwent bail-out stenting, the cumulative 1-, 3-, and 5-year primary IVC patency rates were 100.0%, 88.9%, and 88.9% in the MOVC group and 97.2%, 85.0%, and 77.3% in the SOVC group, respectively (P=0.687; Figure 2 ). There were no significant differences in the cumulative 1-, 3-, and 5-year primary IVC patency rates between balloon dilation alone and bail-out stenting for patients in the MOVC group (P=0.866) or SOVC group (P=0.065).
Two patients in the SOVC group experienced stent fracture. These were identified by computed tomographic angiography during clinical follow-up, one at 26 months and another one at 28 months after treatment. The IVC lumen was still patent in both the patients. Three patients (2 in the SOVC group and 1 in the MOVC group) had right hepatic vein occlusion, and 1 patient in the SOVC group had accessory hepatic vein occlusion caused by stent implantation. All 4 cases of hepatic vein occlusions were successfully treated by balloon angioplasty. None of the patients presented raised creatinine or renal vein thrombosis during follow-up. Five patients (3 in the MOVC group and 2 in the SOVC group) died during follow-up. Three of them died of liver failure, 1 each at 5, 13, and 14 months. One patient died of hepatocellular carcinoma 21 months after stent placement. One patient died of causes unrelated to BCS 12 months after treatment.
Risk Factors for Reocclusion
According to univariate analysis, the risk factors for reocclusion were sex (male), segmental occlusion, increased level of serum alkaline phosphatase (ALP), and decreased levels of serum albumin and hemoglobin. Multivariate analysis confirmed that an increased ALP concentration and segmental occlusion were independent risk factors for reocclusion (Table 4 ). According to receiver-operator characteristic analysis to determine the prognostic value of ALP for reocclusion risk, the area under the receiver-operator characteristic curve was 0.693 (95% confidence interval, 0.597-0.789; P<0.001). For segmental occlusion, the area under the receiver-operator characteristic curve was 0.614 (95% confidence interval, 0.512-0.716; P=0.035; Figure 3 ). The duration of symptoms, prognostic index, and treatment with balloon dilation alone were not correlated with post-treatment reocclusion in this study.
Discussion
In this retrospective study, balloon dilation was used as a primary method of treatment, and adjunctive stent placement was performed whenever there was significant residual stenosis after balloon dilation. Angioplasty of the occluded hepatic veins was not attempted in this study because of the presence of at least 1 patent hepatic or accessory hepatic vein, which was sufficient to maintain venous return to the IVC. 5, 20 In this study, endovascular treatment was technically successful in 263 of 265 BCS patients with IVC obstruction. Long-term follow-up of the 245 patients was carried out, and satisfactory therapeutic outcomes were achieved.
Specific exclusion criteria were established in this study to reduce the influence of confounding factors on the comparison of long-term outcomes of endovascular intervention between patients with MOVC and patients with SOVC. For instance, if stenting was used in SOVC patients with IVC occlusion involving the ostium of the renal veins, the renal veins would be covered by the stent, possibly resulting in renal vein obstruction. However, for patients with MOVC, the occlusion site was far away from the renal veins, and the use of a stent did not affect the renal veins. Therefore, patients with IVC occlusion involving the ostium of the renal veins were excluded to make the 2 groups more comparable. Patients with BCS complicated by hepatocellular carcinoma were also excluded because these patients often had poor prognosis, and this would affect the assessment of long-term outcomes of endovascular management. At least 1 main hepatic or accessory hepatic vein was needed to achieve recanalization in patients with occlusion of all 3 main hepatic veins or accessory hepatic vein. Thus, these patients were excluded to allow better comparisons of the endovascular procedures between the 2 groups. In our routine clinical practice, the prevalence of pediatric BCS is not high, but endovascular treatment with balloon dilation and stent placement is also performed in these patients. However, the IVC diameter and length in pediatric patients is still in the process of growth and development, and this might affect the results of long-term follow-up. Thus, we excluded the pediatric population in this study. In addition, we did not include protein C and protein S in the preinterventional workup because previous research indicated that deficiencies of protein C and protein S were rare in patients with BCS. 21 Furthermore, the examination of protein C and protein S levels is not part of the routine laboratory workup at our center.
In this study, the IVC occlusion in all patients with BCS was complete, and it was usually tenacious and rigid. It was difficult to cross this type of occlusion with a guidewire. Therefore, in the majority of the patients, a pigtail catheter was inserted first via the femoral approach and retained at the distal end of the IVC occlusion to act as a localizer. Then, a steel needle with a curved head was inserted to penetrate the IVC occlusion from the top to the bottom end via the right jugular approach. 17, 18 This dual approach improved the technical success rate and decreased the occurrence of complications, such as IVC perforation and hemopericardium. In most cases of BCS, there was a sufficient distance between the proximal end of the IVC occlusion and the right atrium. Thus, the steel needle could pass through into the right atrium safely and reach the top end of the occlusion. This was helpful to avoid piercing the pericardium in the following penetration. In this study, 2 patients (0.7%) developed pericardial tamponade because the site of the IVC occlusion was close to the right atrium. The incidence of pericardial tamponade of this dual approach was acceptable, when compared with that in a previous report (1.9%). For patients with BCS caused by MOVC, endovascular management of balloon dilation alone can often achieve satisfactory long-term outcomes. Yang et al 13 showed that 38 BCS patients with MOVC underwent balloon angioplasty successfully without stent placement. Only 1 patient experienced recurrence during a follow-up period of ≤8 years. Ciesek et al 23 reported 5 white patients with MOVC, 3 of whom received endovascular treatment with balloon dilation alone. All procedures were successful, and no recurrence occurred during follow-up (mean, 46±11 months). Ding et al 24 reported on 93 patients with BCS who had hepatic venous obstruction (91 had membranous obstruction) with or without IVC obstruction, of which 91 (97.9%) were treated with balloon dilation alone. In that study, long-term outcomes were satisfactory with a low reocclusion rate of 8.9% (8/90 ). In our study, balloon dilation alone was performed in most cases in the MOVC group, and the recurrence rate was 9.6% (11/115), which was similar to that reported by Ding et al. 24 In contrast, Zhang et al 25 used IVC stent placement as the first-choice treatment for MOVC, and long-term outcomes were also excellent. In the MOVC group of our study, there was no significant difference (P=0.866) in long-term IVC patency rates between balloon dilation alone and bail-out stenting. These results show that both balloon dilation and bail-out stenting can result in good long-term IVC patency for the management of MOVC in patients with primary BCS. From the viewpoint of patient costs, balloon dilation alone minimizes the operative cost and procedure complexity, making it a more appropriate first-choice endovascular treatment for patients with MOVC. Moreover, the complications of long-term indwelling stents, such as stent fracture, migration to the heart, and occlusion of the ostium of the hepatic or accessory hepatic veins, 26, 27 serve as a reminder that caution should be used when choosing and placing stents in BCS patients with MOVC.
22
For BCS patients with SOVC, the usage of an IVC stent remained a controversial issue. Srinivas et al 28 successfully treated 5 BCS patients with SOVC by endovascular intervention and 4 of them (80%) underwent initial stent implantation; whereas Wu et al 5 maintained that balloon angioplasty alone should be the optimal treatment for this condition. In our study, 84 of 129 patients underwent balloon dilation alone because there was no significant IVC recoil after balloon dilation. Stent placement was not used unless the residual lesions pushed back into the lumen of the IVC once the balloon catheter was removed. According to our clinical experience, in the majority of primary BCS patients with IVC obstruction (membranous or segmental), there is a weak point in the occlusion. Thus, we used the technique of using a steel needle to find this weak point instead of using brute force for penetration. Sufficient dilation with a balloon catheter along the weak area of IVC obstruction could be helpful to improve the efficacy of balloon dilation alone. During the 72 months of followup, the reocclusion incidence for patients in the SOVC group who underwent balloon dilation alone was 24.3% (19/78 ). This was a better success rate than that described in previous reports on balloon dilation alone. 16, 25 In addition, this was not significantly higher than that for patients in our study who underwent bail-out stenting (12.8%, 5/39; P=0.145). In our opinion, the advantages of our technique played an important role in reducing the need for stent implantation in patients with SOVC in this study.
Although no significant difference was detected for cumulative 1-, 3-, and 5-year primary IVC patency rates between balloon dilation alone and bail-out stenting for patients with SOVC (P=0.065), the results demonstrated that the cumulative 1-, 3-, and 5-year primary IVC patency rates for patients who underwent balloon dilation alone were lower in the SOVC group than those in the MOVC group (P=0.001). Thus, the long-term outcomes of balloon dilation alone were worse in BCS patients with SOVC than in those with MOVC, resulting in lower longterm treatment efficacy of endovascular management for BCS patients with SOVC (P=0.007). Indeed, stent implantation was used more frequently for patients with SOVC in several previous reports. 16, 25, 28 Zhang et al 25 reported on 115 patients with BCS, in whom stents were placed whether they had MOVC or SOVC. At a mean follow-up of 45 months, stent patency reached 90%. Our study showed that the primary IVC patency rate for patients who underwent stent placement was 87.2% (34/39) in the SOVC group, which was consistent with the previous study.
Patients who presented IVC reocclusion during follow-up were suggested to undergo another balloon angioplasty, and secondary stent placement was recommended for both SOVC and MOVC patients if IVC recoiled >50% intraoperatively after balloon dilation. In addition, multivariate analysis in our study showed that SOVC was an independent risk factor for reocclusion in patients with BCS receiving endovascular management. Therefore, to decrease the rate of reocclusion, it is reasonable to recommend stent placement more strongly for patients with SOVC. Furthermore, we found that increased ALP was an independent risk factor for reocclusion. Previous reports demonstrated that elevation of ALP in patient with BCS was caused by an intrahepatic cholestatic process secondary to hepatic venous outflow obstruction. 29 Our results further indicated that elevated ALP levels positively correlated with reocclusion in patients with BCS after endovascular treatment. This is a finding that has not been demonstrated in other research, indicating that higher ALP levels may play a role in the occurrence of reocclusion.
Conclusions
The long-term treatment outcome of endovascular management was better for primary BCS patients with MOVC than for those with SOVC. For BCS patients with MOVC, balloon dilation alone could be the optimal treatment and stent placement should be used as a bail-out only when there is a technical angioplasty failure. For BCS patients with SOVC, the efficacy of balloon dilation alone was worse than that for MOVC patients and stenting should be more strongly recommended for these patients.
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